首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal CD30 Antibody

  • 中文名： CD30抗体
  • 别    名： TNFRSF8; Ki-1; D1S166E
货号: IPD32025
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 1/200 - 1/1000 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

AliasesTNFRSF8; Ki-1; D1S166E
Entrez GeneID943
clone2A5A4
WB Predicted band size63.7kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD30 (AA: 416-595) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

参考文献

以下是关于CD30抗体的3篇代表性文献及其摘要概括：

---

1. **文献名称**：*Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas*

**作者**：Younes A, et al.

**摘要**：本文报道了抗CD30抗体药物偶联物Brentuximab vedotin在复发/难治性CD30阳性霍奇金淋巴瘤和间变性大细胞淋巴瘤中的临床研究，证实其显著缓解率与安全性，奠定其作为靶向治疗的基础。

2. **文献名称**：*CD30 as a therapeutic target in lymphoma*

**作者**：Sasson SC, et al.

**摘要**：综述CD30的生物学功能及其在淋巴瘤中的表达特征，系统分析靶向CD30的单克隆抗体(如Brentuximab)及新型免疫疗法的机制、临床进展与挑战。

3. **文献名称**：*Combination therapy with anti-PD-1 and CD30-targeted antibody-drug conjugate in Hodgkin lymphoma*

**作者**：Diefenbach CS, et al.

**摘要**：探讨抗PD-1免疫检查点抑制剂与CD30抗体药物偶联物的联合治疗方案，显示协同增效作用，为改善霍奇金淋巴瘤患者生存率提供新策略。

---

以上文献涵盖CD30抗体的临床研究、机制综述及联合治疗方向，反映其在血液肿瘤治疗中的关键作用。

背景信息

CD30. a transmembrane glycoprotein in the tumor necrosis factor receptor (TNFR) superfamily, is primarily expressed on activated lymphocytes and malignant cells in certain lymphomas, including Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). Its restricted expression in healthy tissues makes it an attractive therapeutic target. CD30 antibodies were initially developed as naked monoclonal antibodies (e.g., SGN-30) to induce apoptosis or immune-mediated cytotoxicity. However, clinical efficacy was limited, prompting the development of antibody-drug conjugates (ADCs). Brentuximab vedotin, an ADC combining an anti-CD30 antibody with the microtubule-disrupting agent MMAE, revolutionized treatment upon its 2011 approval. It delivers targeted chemotherapy to CD30-positive cells, improving outcomes in relapsed/refractory HL and ALCL. Beyond ADCs, CD30-targeting bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies are under investigation. Research also explores CD30’s role in modulating immune responses, as it participates in co-stimulatory signaling pathways. Despite successes, challenges like resistance mechanisms and optimizing combination regimens remain active areas of study. CD30 antibodies exemplify the shift toward precision oncology, balancing targeted efficacy with reduced off-tumor toxicity. Ongoing trials aim to expand applications to other CD30-positive malignancies and refine biomarker-driven approaches.

客户数据及评论

折叠内容

大包装询价

×